Literature DB >> 31553842

Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?

Richard J Farrell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31553842     DOI： 10.1056/NEJMe1910742

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  The Protective Effect of Sulforaphane on Dextran Sulfate Sodium-Induced Colitis Depends on Gut Microbial and Nrf2-Related Mechanism.

Authors:  Canxia He; Mingfei Gao; Xiaohong Zhang; Peng Lei; Haitao Yang; Yanping Qing; Lina Zhang
Journal:  Front Nutr       Date:  2022-06-27

Review 2.  Vedolizumab in Inflammatory Bowel Disease: West versus East.

Authors:  Prasanta Debnath; Pravin M Rathi
Journal:  Inflamm Intest Dis       Date:  2021-01-27

3.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

4.  Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice.

Authors:  Lenka Jourova; Stefan Satka; Veronika Frybortova; Iveta Zapletalova; Pavel Anzenbacher; Eva Anzenbacherova; Petra Petr Hermanova; Barbora Drabonova; Dagmar Srutkova; Hana Kozakova; Tomas Hudcovic
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 5.  Ulcerative colitis: Recent advances in the understanding of disease pathogenesis.

Authors:  Ross J Porter; Rahul Kalla; Gwo-Tzer Ho
Journal:  F1000Res       Date:  2020-04-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.